“As of November 2020, late-stage clinical stud

“As of November 2020, late-stage clinical studies for numerous repurposed antibody therapeutics (Table 1) were recruiting patients, and emergency use authorizations (EUAs) had been requested or granted for 3, anti-IL-6 receptor levilimab, anti-CD6 itolizumab, and anti-C-C chemokine receptor type 5 (CCR5) leronlimab.“

Looks like they did request EUA for CD10 ? Although they said they didn’t? Maybe this is accurate but I found it interesting.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833761/

I find it comical and also disgusting at the same time how BP get EUA for all their drugs while Leronlimab sits on the shelves. What a joke.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech